Advancis Pharmaceutical to Present at Thomas Weisel Partners Healthcare Conference
01 September 2006 - 5:26PM
PR Newswire (US)
Presentation Will Be Webcast Live and Archived on Company's Web
Site GERMANTOWN, Md., Sept. 1 /PRNewswire-FirstCall/ -- Advancis
Pharmaceutical Corporation (NASDAQ:AVNC), a pharmaceutical company
focused on developing and commercializing novel anti-infective
products, today announced that Dr. Edward M. Rudnic, Advancis
president and CEO, will deliver a corporate presentation on Friday,
September 8, 2006, at 10:55 a.m. Eastern Time. The presentation
will take place as part of the Thomas Weisel Partners Healthcare
Conference 2006 at the Four Seasons Hotel Boston in Boston,
Massachusetts. Dr. Rudnic's remarks will be available live on the
Advancis web site, where they also will be archived for 30 days. To
access the presentation, log on to http://www.advancispharm.com/
and click on the Presentations option in the Investor Relations
section. Please connect to the web site several minutes prior to
the start of the live presentation to ensure adequate time for any
software download that may be necessary. About Advancis
Pharmaceutical: Advancis Pharmaceutical Corporation (NASDAQ:AVNC)
is a pharmaceutical company focused on the development and
commercialization of pulsatile drug products that fulfill
substantial unmet medical needs in the treatment of infectious
disease. The Company is developing anti-infective drugs based on
its novel biological finding that bacteria exposed to antibiotics
in front- loaded staccato bursts, or "pulses," are killed more
efficiently and effectively than those under standard treatment
regimens. Based on this finding, Advancis has developed a
proprietary, once-a-day pulsatile delivery technology called
PULSYS. By examining the resistance patterns of bacteria and
applying its delivery technologies, Advancis has the potential to
redefine infectious disease therapy and significantly improve drug
efficacy, shorten length of therapy, and reduce drug resistance
versus currently available antibacterial products. For more on
Advancis, please visit http://www.advancispharm.com/. DATASOURCE:
Advancis Pharmaceutical Corporation CONTACT: Robert Bannon, Sr.
Director, Investor Relations of Advancis Pharmaceutical
Corporation, +1-301-944-6710, or Web site:
http://www.advancispharm.com/
Copyright
Advancis (NASDAQ:AVNC)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
Advancis (NASDAQ:AVNC)
Historical Stock Chart
Von Jun 2023 bis Jun 2024
Echtzeit-Nachrichten über Advancis Pharmaceutical (MM) (NASDAQ): 0 Nachrichtenartikel
Weitere Advancis Pharmaceutical (MM) News-Artikel